Biodegradable hyaluronan (hyaluronic acid, HA) made insoluble by self-cross-linking in the presence of N-(3-dimethylaminopropyl)-N′-ethyl carbodiimide (EDC) has been used to cover stents. The maximum polymer-mass on a 16-mm stainless steel stent is approximately 2 mg. During manual crimping and simulated application, the loss of polymerized HA is negligible. The insoluble HA coating has an advantageous inherent antiproliferative effect regarding neointimal formation after local vessel wall injury (overstretch model) and leads to a reduced inflammatory response compared to uncoated stainless-steel stents, used as control, in undiseased pig coronary arteries, over a follow-up period of four weeks. Thus, cross-linked HA stent coating warrants further research as an interactive degradable biomaterial with an inherent inhibitory effect on neointimal formation as a possible biomatrix for local drug delivery to reduce restenosis rate.
FarbA., SangiorgiG., CarterA.J.Pathology of acute and chronic coronary stenting in humans.Circulation1999; 99: 44–52.
2.
GreweP., DenekeT., MachraouiA.Acute and chronic tissue response to coronary stent implantation: Pathologic findings in human specimen.J Am Coll Cardiol2000; 35: 157–63.
3.
KimuraT., AbeK., ShizutaS.Long-term clinical and angiographic follow-up after coronary stent placement in native coronary arteries.Circulation2001; 104: 928–33.
4.
HeubleinB., PethigK., ElsayedA.M.Silicon carbide coating: a semiconducting hybrid design of coronary stents: a feasibility study.J Invasive Cardiol1998; 10: 255–62.
5.
WhelanD.M., van der GiessenW.J., KrabbendamS.C.Biocompatibility of phosphorylcholine coated stents in normal porcine coronary arteries.Heart2000; 83: 338–45.
6.
SuzukiT., KopiaG., HayashiS-IStent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model.Circulation2001; 104: 1188–93.
7.
SouzaJ.E., CostaM.A., AbizaidA.C.Sustained suppression of neointimal proliferation by sirolimus-eluting stents. One-year angiographic and intravascular ultrasound follow-up.Circulation2001; 104: 2007–11.
8.
TeirsteinP.S.Living the dream of no restenosis.Circulation2001; 104: 1996–8.
9.
HeldmanA.W., ChengL., JenkinsM.Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis.Circulation2001; 103: 2289–95.
10.
AltE., HaehnelI., BeilharzC.Inhibition of neointimal formation after experimental coronary artery stenting: A new biodegradable stent coating releasing hirudin and the prostacyclin analogue iloprost.Circulation2000; 101: 1453–8.
11.
Van der GiessenW.J., LincoffA.M., SchwartzR.S.Marked inflammatory sequelae to implantation of biodegradable and non-biodegradable polymers in porcine coronary arteries.Circulation1996; 94: 1690–7.
12.
YamawakiT., ShimokawaH., KozaiT.Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo.J Am Coll Cardiol1998; 32: 780–6.
13.
TamaiH., IgakiK., KyoE.Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in human.Circulation2000; 102; 399–404.
14.
CookA.D., HrkachJ.S., GaoN.N.Characterization and development of RGD-peptide-modified poly(lactic acid-co-lysine) as an interactive, resorbable biomaterial.J Biomed Mater Res1997, 35: 513–23.
15.
SavaniR.C., WangC., YangB.Migration of bovine aortic smooth muscle cells after wounding injury. The role of hyaluronan and RHAMM.J Clin Invest1995; 95: 1158–68.
16.
MohapartaS., YangX., WrightJ.A.Soluble hyaluronan receptor RHAMM induces mitogenic arrest by suppressing Cdc2 and cyclin B1 expression.J Exp Med1996; 183: 1663–88.
17.
SavaniR.C., TurleyE.A.The role of hyaluronan and its receptors in restenosis after balloon angioplasty: development of a potential therapy.Int J Tissue React1995; 17: 141–51.
18.
SamuelS.K., HurtaR.A.R., SpearmanM.A.TGF-ß1 stimulation of cell locomotion is mediated by the hyaluronan receptor RHAMM and hyaluronan.J Cell Biol1993; 123: 749–58.
19.
JamM., HeQ., LeeW.S.Role of CD44 in the reaction of vascular smooth muscle cells to arterial wall injury.J Clin Invest1996; 97: 596–603.
20.
PapakonstantinouF., Karakiulakis 6, EickelbergOA 340 kDa hyaluronic acid secreted by human vascular smooth muscle cells regulates their proliferation and migration.Glycobiology1998; 8: 821–30.
21.
SmedrodB.Cellular events in the uptake and degradation of hyaluronan.Adv Drug Del Rev1991; 7: 265–78.
22.
TomihataK., IkadaY.Crosslinking of hyaluronic acid with water-soluble carbodiimide.J Biomed Mater Res1997; 37: 243–51.
SchwartzR.S., EdwardsW.D., BaileyK.R.Differential neointimal response to coronary artery injury in pigs and dogs. Implications for restenosis models.Arterioscler Thromb1994; 14: 395–400.
25.
SchwartzR.S., HuberK.C., MurphyJ.G.Restenosis and the proportional neointimal response to coronary artery injury: Results in a porcine model.J Am Coll Cardiol1992; 19: 267–74.
26.
TravisJ.A., HughesM.G., WongJ.M.Hyaluronan enhances contraction of collagen by smooth muscle cells and adventitial fibroblasts: Role of CD 44 and implications for constrictive remodeling.Circ Res2001; 88: 77–83.
27.
OertliB., Beck-SchimmerB., FanX.Mechanisms of hyaluronan- induced up-regulation of ICAM-1 and VCAM-1 expression by murine kidney tubular epithelial cells: hyaluronan triggers cell adhesion molecule expression through a mechanism involving activation of nuclear factor-kappa B and activating protein-1.J Immunol1998; 161: 3431–7.
28.
LambR.F., HenniganR.F., TumbullK.AP-1 mediated invasion requires increased expression of the hyaluronan receptor CD 44.Mol Cell Biol1997; 17: 963–76.
29.
ZhongS.P., CampocciaD., DohertyP.J.Biodegradation of hyaluronic acid derivatives by hyaluronidase.Biomaterials1994; 15: 359–65.
